IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma

Mengxiang Zhao,Yijia He,Nisha Zhu,Yuxian Song,Qingang Hu,Zhiyong Wang,Yanhong Ni,Liang Ding
DOI: https://doi.org/10.1038/s41416-022-02090-0
IF: 9.075
2022-12-04
British Journal of Cancer
Abstract:Loss-of-function of PD-L1 induces therapy resistance of anti-PD-1/L1 therapy, and the complex regulatory mechanisms are not completely understood. We previously reported that stroma-derived interleukin-33 (IL-33) promoted the progression of oral squamous cell carcinoma (OSCC). We here focused on the immune-regulation role of IL-33 and its receptor ST2 signaling in PD-L1-positive OSCC patients.
oncology
What problem does this paper attempt to address?